IDYA News and Press, IDEAYA Biosciences Inc. From 07/08/24

2024-07-08 07:58:27 ET Ideaya Biosciences ( NASDAQ: IDYA ) shares jumped as much as 23% premarket on Monday after the oncology company reported positive interim data from an expansion dose cohort of a mid-stage trial of IDE397.... Read the full article on Seeking Alpha...

IDEAYA Announces Positive Interim Phase 2 Monotherapy Expansion Data for IDE397 a Potential First-in-Class MAT2A Inhibitor in MTAP-Deletion Urothelial and Lung Cancer PR Newswire ~39% Overall Response Rate ( ORR ): 1 CR and 6 PRs (2 awaiting confirmation) by RECIST 1.1 out...

IDEAYA Announces Investor Webcast to Report Clinical Data Update for IDE397 Phase 2 Monotherapy Expansion Dose in MTAP-Deletion Urothelial and Lung Cancer on Monday, July 8, 2024 PR Newswire SOUTH SAN FRANCISCO, Calif. , July 5, 2024 /PRNewswire/ -- IDEAYA Biosci...

IDEAYA Biosciences Announces First-Patient-In for Phase 1 Clinical Trial Evaluating IDE397 and Trodelvy® Combination in MTAP-Deletion Bladder Cancer PR Newswire First-Patient-In (FPI) for Phase 1 combination treatment with IDE397, IDEAYA's MAT2A inhibitor, and Trodelvy ...

IDEAYA Biosciences Announces Clinical Program Updates for IDE397 a Potential First-in-Class Phase 2 MAT2A Inhibitor Targeting MTAP-Deletion Solid Tumors PR Newswire Targeting IDE397 Phase 2 monotherapy expansion dose clinical data update in over ~15 evaluable MTAP lung an...

2024-06-18 11:23:25 ET Summary The stock of Ideaya Biosciences, Inc. has risen some 50% since we last visited this clinical stage development firm focused on "synthetic lethality." The company continues to advance its pipeline, has partnerships with several Big Pharma names, and h...

2024-06-13 11:02:01 ET More on Evergy, Coca-Cola, etc. Atlassian: Time To Initiate A Position, As Management Continues To Exceed Expectations Coca-Cola: 30%+ Upside If Dollar Gains Revert In 2024/2025 The Coca-Cola Company (KO) dbAccess Global Consumer Conference (Tr...

IDEAYA Announces Results for Darovasertib Phase 2 IST in Neoadjuvant Uveal Melanoma at ASCO and Clinical Update for Phase 2 Company-Sponsored Neoadjuvant Study PR Newswire 75% eye preservation rate (9 of 12 enucleation patients) ~67% (8 of 12 enucleation patients...

IDEAYA Biosciences to Participate in Upcoming June 2024 Investor Relations Events PR Newswire SOUTH SAN FRANCISCO, Calif. , May 29, 2024 /PRNewswire/ -- IDEAYA Biosciences, Inc. (NASDAQ: IDYA), a precision medicine oncology company committed to the discovery...

IDEAYA Biosciences Appoints Daniel A. Simon as Chief Business Officer to Lead Corporate Strategy and Business Development PR Newswire Over 18-years at leading life sciences and strategy consulting companies, including Revolution Medicines, Guardant Health, Onyx Pharmaceut...